The market seems to have forgotten these upcoming catalysts:Q1 2019 - aGVHD BLA filed with FDA .
Q1 2019 - Meeting with FDA to discuss filing of BLA under RMAT for phase 2b LVAD - SI is confident FDA will accept a BLA for efficacy in GI bleeding alone (and so am I).
Q1 2019 - has everyone forgotten that CLBP phase 3 trial completed enrollment in Q1 2018; so 12-months results are due in March 2019 (we will have to wait another year for 24-month results, but could be good enough to put it back in the radar)
Q2 2019 - BLA filing with FDA for LVAD (hopeful). If done, then approval in Q3 under RMAT.
Q3 2019 - FDA approves aGVHD (this is a done deal). Revenues from sales should start in September 2019.
Q4 2019 - revenues start for LVAD treatment.
Q1 2020 - 12-month topline data for CHF phase 3 trial.
Q2 2020 - Mesoblast sold for USD 20 billion (my prediction).
Cheers.
MSB Trading - 2019, page-57
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.070(6.45%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $20.88M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 59978 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 34019 | 3 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.070 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3733217 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |